share_log

CONMED (NASDAQ:CNMD) Downgraded by StockNews.com to Sell

Financial News Live ·  Aug 5, 2022 05:21

StockNews.com downgraded shares of CONMED (NASDAQ:CNMD – Get Rating) from a hold rating to a sell rating in a research note published on Monday morning.

CONMED Trading Down 3.5 %

Shares of CNMD stock opened at $96.53 on Monday. The stock has a 50-day moving average price of $99.43. The company has a debt-to-equity ratio of 1.46, a current ratio of 2.87 and a quick ratio of 1.43. CONMED has a 12 month low of $87.24 and a 12 month high of $159.11.

Get CONMED alerts:

CONMED (NASDAQ:CNMD – Get Rating) last announced its quarterly earnings data on Wednesday, May 4th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.08. The firm had revenue of $242.33 million during the quarter, compared to analyst estimates of $235.55 million. CONMED had a positive return on equity of 13.94% and a negative net margin of 10.93%. Equities analysts forecast that CONMED will post 3.32 EPS for the current fiscal year.

About CONMED

(Get Rating)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.

Featured Articles

  • Get a free copy of the StockNews.com research report on CONMED (CNMD)
  • 3 Hotel Stocks to Consider Checking into After Earnings
  • How Does Freeport McMoran Inc Compare to Its Sector Competitors?
  • Can FuelCell Energy Surge Higher This Year?
  • Is It Time to Take a Ride on Cedar Fair Stock?
  • Time To Take A Serious Look At Nikola Stock As Production Starts

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment